Reported Tuberculosis in the United States, 2021
Table 18. Percentages of Tuberculosis Cases by Initial Drug Regimen, Method of Administration, and Completion of Therapy (COT): United States, 1993–2021
See Surveillance Slides #42, #43, #44, #45 and #46.
| Year | Total cases1 | Initial drug regimen2 | Method of administration3, 4 | Therapy ≤1 year indicated5 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRZE6 | Multi (4+) drug regimen7 | No. | DOT only | Both DOT and SAT | No. | COT ≤1 year | COT ever | ||||||||
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||||
| 2021 | 7,604 | 6,330 | (83.2) | 794 | (10.4) | –– | –– | –– | –– | –– | –– | –– | –– | –– | –– |
| 2020 | 6,955 | 5,801 | (83.4) | 745 | (10.7) | –– | –– | –– | –– | –– | –– | –– | –– | –– | –– |
| 2019 | 8,665 | 7,177 | (82.8) | 1,017 | (11.7) | 8,632 | 5,241 | (62.2) | 2,778 | (33.0) | 7,189 | 6,460 | (89.9) | 6,863 | (95.5) |
| 2018 | 8,786 | 7,287 | (82.9) | 1,029 | (11.7) | 8,738 | 5,269 | (61.2) | 2,903 | (33.7) | 7,355 | 6,574 | (89.4) | 7,048 | (95.8) |
| 2017 | 8,886 | 7,450 | (83.8) | 925 | (10.4) | 8,843 | 5,357 | (61.2) | 2,875 | (32.8) | 7,394 | 6,686 | (90.4) | 7,132 | (96.5) |
| 2016 | 9,019 | 7,669 | (85.0) | 913 | (10.1) | 8,977 | 5,660 | (63.9) | 2,701 | (30.5) | 7,575 | 6,768 | (89.3) | 7,262 | (95.9) |
| 2015 | 9,313 | 7,951 | (85.4) | 859 | (9.2) | 9,281 | 5,997 | (65.0) | 2,625 | (28.5) | 7,852 | 7,083 | (90.2) | 7,577 | (96.5) |
| 2014 | 9,174 | 7,831 | (85.4) | 838 | (9.1) | 9,148 | 5,786 | (63.8) | 2,645 | (29.1) | 7,709 | 6,959 | (90.3) | 7,467 | (96.9) |
| 2013 | 9,295 | 7,860 | (84.6) | 887 | (9.5) | 9,259 | 5,753 | (63.2) | 2,620 | (28.8) | 7,762 | 6,974 | (89.8) | 7,479 | (96.4) |
| 2012 | 9,694 | 8,283 | (85.4) | 872 | (9.0) | 9,659 | 5,826 | (61.8) | 2,751 | (29.2) | 8,093 | 7,298 | (90.2) | 7,812 | (96.5) |
| 2011 | 10,216 | 8,706 | (85.2) | 825 | (8.1) | 10,175 | 6,161 | (62.3) | 2,882 | (29.1) | 8,463 | 7,594 | (89.7) | 8,167 | (96.5) |
| 2010 | 10,802 | 9,127 | (84.5) | 875 | (8.1) | 10,752 | 6,315 | (59.3) | 3,304 | (31.0) | 9,049 | 8,107 | (89.6) | 8,696 | (96.1) |
| 2009 | 11,222 | 9,466 | (84.4) | 872 | (7.8) | 11,159 | 6,603 | (59.7) | 3,344 | (30.2) | 9,494 | 8,434 | (88.8) | 9,077 | (95.6) |
| 2008 | 12,679 | 10,678 | (84.2) | 965 | (7.6) | 12,602 | 7,038 | (56.5) | 4,165 | (33.4) | 11,068 | 9,532 | (86.1) | 10,333 | (93.4) |
| 2007 | 12,973 | 10,874 | (83.8) | 847 | (6.5) | 12,898 | 7,192 | (56.3) | 4,214 | (33.0) | 11,406 | 9,747 | (85.5) | 10,696 | (93.8) |
| 2006 | 13,396 | 11,157 | (83.3) | 880 | (6.6) | 13,310 | 7,612 | (57.5) | 4,022 | (30.4) | 11,645 | 9,868 | (84.7) | 10,846 | (93.1) |
| 2005 | 13,754 | 11,511 | (83.7) | 689 | (5.0) | 13,666 | 7,840 | (57.9) | 4,012 | (29.6) | 11,945 | 10,029 | (84.0) | 11,045 | (92.5) |
| 2004 | 14,193 | 11,697 | (82.4) | 694 | (4.9) | 14,079 | 8,181 | (58.9) | 3,857 | (27.8) | 12,359 | 10,414 | (84.3) | 11,436 | (92.5) |
| 2003 | 14,478 | 11,775 | (81.3) | 683 | (4.7) | 14,376 | 8,051 | (56.5) | 4,056 | (28.5) | 12,641 | 10,562 | (83.6) | 11,722 | (92.7) |
| 2002 | 14,695 | 11,802 | (80.3) | 630 | (4.3) | 14,563 | 7,972 | (55.4) | 3,996 | (27.8) | 12,712 | 10,543 | (82.9) | 11,752 | (92.4) |
| 2001 | 15,536 | 12,403 | (79.8) | 606 | (3.9) | 15,407 | 8,159 | (53.7) | 4,186 | (27.5) | 13,510 | 11,141 | (82.5) | 12,521 | (92.7) |
| 2000 | 15,869 | 12,457 | (78.5) | 670 | (4.2) | 15,782 | 8,190 | (52.5) | 4,029 | (25.8) | 13,730 | 11,280 | (82.2) | 12,702 | (92.5) |
| 1999 | 16,941 | 13,019 | (76.8) | 792 | (4.7) | 16,855 | 8,182 | (49.4) | 4,572 | (27.6) | 14,659 | 11,931 | (81.4) | 13,508 | (92.1) |
| 1998 | 17,727 | 13,167 | (74.3) | 761 | (4.3) | 17,585 | 8,240 | (47.7) | 4,594 | (26.6) | 15,230 | 12,370 | (81.2) | 14,040 | (92.2) |
| 1997 | 19,063 | 13,714 | (71.9) | 828 | (4.3) | 18,932 | 8,702 | (47.0) | 4,411 | (23.8) | 16,326 | 12,849 | (78.7) | 14,861 | (91.0) |
| 1996 | 20,424 | 13,750 | (67.3) | 894 | (4.4) | 20,300 | 8,437 | (42.5) | 4,452 | (22.4) | 17,412 | 13,369 | (76.8) | 15,711 | (90.2) |
| 1995 | 21,850 | 13,704 | (62.7) | 1,058 | (4.8) | 21,706 | 7,856 | (37.3) | 4,532 | (21.5) | 18,454 | 13,671 | (74.1) | 16,461 | (89.2) |
| 1994 | 23,197 | 12,925 | (55.7) | 1,287 | (5.5) | 23,053 | 6,190 | (28.1) | 4,528 | (20.5) | 19,452 | 13,343 | (68.6) | 16,890 | (86.8) |
| 1993 | 23,964 | 9,664 | (40.3) | 1,185 | (4.9) | 23,743 | 5,052 | (21.7) | 3,355 | (14.4) | 19,899 | 12,621 | (63.4) | 17,115 | (86.0) |
1Persons alive at diagnosis with initial drug regimen information.
2In the 50 U.S. states, New York City, and District of Columbia: In 2021, 70 (0.9%) received no initial drug therapy and 20 (0.3%) were started on one drug.
3Persons on an initial drug therapy with at least one drug.
4DOT, directly observed therapy; SAT, self-administered therapy.
5Excludes patients who died within one year of initiating therapy; patients with an initial isolate resistant to rifampin; patients with bone and joint disease, meningeal disease, or disease of the central nervous system; or patients <15 years of age with miliary disease, positive blood culture, or a positive nucleic acid amplification test on a blood specimen. Beginning in 2011, patients who moved out of the country within one year of initiating therapy were also excluded.
6H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol.
7A drug regimen with at least four drugs, other than HRZE.
Note: Data for all years are updated through July 8, 2022.
Double dashes (––) indicate that data are not available.
See Technical Notes